152 related articles for article (PubMed ID: 30108461)
1. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.
Mukri MNA; Kong WY; Mustafar R; Shaharir SS; Shah SA; Abdul Gafor AH; Mohd R; Abdul Cader R; Kamaruzaman L
EXCLI J; 2018; 17():563-575. PubMed ID: 30108461
[No Abstract] [Full Text] [Related]
2. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
4. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
6. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Zhang X; Wan D; Yang G; Peng Q; Wang X
Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
[TBL] [Abstract][Full Text] [Related]
9. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
11. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
12. Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia.
Gohda T; Yanagisawa N; Murakoshi M; Ueda S; Nishizaki Y; Nojiri S; Ohashi Y; Ohno I; Shibagaki Y; Imai N; Iimuro S; Kuwabara M; Hayakawa H; Kimura K; Hosoya T; Suzuki Y
Front Med (Lausanne); 2021; 8():634932. PubMed ID: 34322499
[No Abstract] [Full Text] [Related]
13. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
14. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis.
Kim S; Kim HJ; Ahn HS; Oh SW; Han KH; Um TH; Cho CR; Han SY
Kidney Res Clin Pract; 2017 Sep; 36(3):274-281. PubMed ID: 28904879
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.
Beddhu S; Filipowicz R; Wang B; Wei G; Chen X; Roy AC; DuVall SL; Farrukh H; Habib AN; Bjordahl T; Simmons DL; Munger M; Stoddard G; Kohan DE; Greene T; Huang Y
Can J Kidney Health Dis; 2016; 3():2054358116675343. PubMed ID: 28270924
[TBL] [Abstract][Full Text] [Related]
18. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Yang AY
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
[TBL] [Abstract][Full Text] [Related]
19. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
20. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
